In Kazakhstan, new effective regimens of prophylactic treatment of tuberculosis infection using the drug «Rifapentin» have been introduced, reducing treatment from 6 months to 1-3 months.
8,633 people (55% children, 45% adults) were covered by prophylactic treatment of tuberculosis infection for 6 months in 2025 — the efficiency is 93% (the WHO standard is at least 90% achieved).
Prophylactic treatment of tuberculosis infection plays a key role in preventing the spread and development of an active form of the disease, especially among high-risk groups for tuberculosis.
In the Republic of Kazakhstan, treatment and diagnosis of tuberculosis are carried out free of charge, within the guaranteed amount of free medical care. Patients with tuberculosis are provided with full access to effective treatment regimens without the use of injectable drugs.
Shortened terms of treatment of tuberculosis with multiple drug resistance from 24 months to 9-12 months.
A pilot project is being implemented to implement a new treatment regimen for drug-resistant tuberculosis, recommended by the WHO, using the drug Pretomanid (BPaL/BPalM), which reduces the duration of treatment to 6 months.
Thanks to our measures, the effectiveness of the treatment of drug-sensitive tuberculosis for 6 months of 2025 was 90.8% (the WHO standard was at least 90%), and drug-resistant tuberculosis was 86.4% (the WHO standard was at least 80%).
An established accounting system, all cases of tuberculosis are registered in the information system «National Register of Tuberculosis Patients». Systematic monitoring and assessment of anti-tuberculosis measures.
In the country, 455 offices of phthisis doctors and 2564 offices of directly controlled treatment (NCL) work for controlled treatment at the outpatient stage.